December 6, 2016
Novartis Pharma said on December 5 that it has filed an application seeking approval of a combination therapy of the BRAF inhibitor Tafinlar (dabrafenib) and the MEK inhibitor Mekinist (trametinib) for the treatment of non-small cell lung cancer (NSCLC). Tafinlar...read more